newsfilter
← Latest News
PR Newswire·

OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits

OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing...